Table 2.

Baseline and annual clinical, laboratory, and MRI characteristics according to MRI evidence of erosion progression at 1 year in patients with RA in remission. Values are mean ± SD, unless otherwise indicated.

CharacteristicsProgression, n = 19Baseline No Progression, n = 37pProgression, n = 191 Year No Progression, n = 37p
Clinical variables
  SJC66, median (range)3 (1–9)2 (0–4)0.250 (0–0)0 (0–0)0.39
  TJC68, median (range)6 (2–16)3 (1–5.5)0.0520 (0–0)0 (0–0)1.0
  DAS284.5 ± 1.53.6 ± 1.10.0501.8 ± 0.51.9 ± 0.50.65
  SDAI22.2 ± 17.213.6 ± 8.00.0503.1 ± 2.72.4 ± 2.20.42
  HAQ score0.684 ± 0.6710.451 ± 0.4120.330.200 ± 0.2870.164 ± 0.3000.61
  ESR, < 20 mm/h28.3 ± 20.919.8 ± 13.60.1311.1 ± 8.015.5 ± 12.40.16
  CRP, < 0.8 mg/dl2.1 ± 2.20.6 ± 0.80.010.3 ± 0.20.3 ± 0.20.98
  VAS pain, 0–100 mm43.9 ± 22.036.1 ± 19.70.2822.1 ± 18.420.1 ± 22.50.46
  PGA, 0–100 mm42.1 ± 22.335.4 ± 18.60.3420.0 ± 19.616.3 ± 17.90.55
MRI variables
  RAMRIS synovitis (0–21)6.3 ± 3.45.9 ± 2.90.714.6 ± 2.03.7 ± 2.60.11
  RAMRIS BME (0–69)8.3 ± 9.43.7 ± 6.10.094.8 ± 5.61.4 ± 2.60.03
  RAMRIS erosion (0–230)9.9 ± 13.65.1 ± 5.10.5513.5 ± 15.04.4 ± 5.00.001
  Total RAMRIS (0–320)24.5 ± 20.014.9 ± 11.90.2223.0 ± 20.210.1 ± 9.30.001
  Tenosynovitis (0–26)7.0 ± 5.86.8 ± 6.70.553.4 ± 2.82.7 ± 4.90.059
  • CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints (tender and swollen); ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; MRI: magnetic resonance imaging; RAMRIS: Rheumatoid Arthritis MRI Score; SDAI: Simplified Disease Activity Index; SJC: swollen joint count in 66 joints; TJC: tender joint count in 68 joints; VAS: visual analog scale; PGA: patient global assessment; BME: bone marrow edema; RA: rheumatoid arthritis.